Allopurinol to Prevent Cirrhosis Related Morbidities

• Status: Not yet recruiting
• Trial end date: 2025-10-30
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to compare the potential benefit of allopurinol in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Allopurinol

Criteria

Inclusion Criteria:

• ge 18 to 75 years old Both sex Adults with cirrhosis in a stable conditions

Exclusion Criteria:

• Active SBP Renal insufficiency (serum creatinine > 2.0 mg/dl) Active GIT hemorrhage